<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201405133954N7</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2015-04-26</date_registration>
      <primary_sponsor>Vice chancellor for research Hamehan University of Medical Sciences</primary_sponsor>
      <public_title>Intravenous Acetaminophen analgesic effects  and improvement of cardiac function   in myocardial infarction</public_title>
      <acronym></acronym>
      <scientific_title>The role of intravenous Acetaminophen versus intravenous Morphine sulfate in pain management and improvement of cardiac function in post acute MI patients who admitted to Hamadan Ekbatan Hospital</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2014-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/4141</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Condition 1: Acute myocardial infarction. Condition 2: Analgesia.</hc_freetext>
      <i_freetext>Intervention 1: All patients will receive  initial treatment of myocardial infarction in arrival emergency department.The treatment consists of oxygen by nasal, oral aspirin 325 mg, sublingual nitrate for up to 3 doses and initial dose of intravenous morphine 3 mg .&#13;
The intervention group will receive 4 doses of acetaminophen 1 gram intravenously every 6 hours, dissolved in 100 mL of normal saline. &#13;
 Methods: 70 pack of dark colors written on them from 1 to 70 are randomly divided into two groups of 35.Inside each envelope is a card on which the letters A (acetaminophen treatment group) or the letter B (morphine treatment group) is written.The letter A or B can be placed inside the envelope are determined using a random numbers table.The first patient to be admitted, we're open Envelope 1 , and patients indicates that the card is inserted into envelopes .Similarly, during the study,for each patient who is eligible for inclusion special envelopes will be opened by the numbers and them placed in the specified group.Pain score using Visual Analogue Scale for0, 0.5, 1, 2, 4, 6, 12, 18 and 24 hours after MI is measured.   Also in 0 , 0.5 , 1, 2, 4, 6, 12, 18 and 24 hours post-MI patients' blood pressure and heart rate will be measured .&#13;
 All patients underwent echocardiography 3 days and 6 weeks after MI then ischemic complications involving Hypokinesia, Akinesia and Dyskinesia  and Ejection Fraction will be measure by&#13;
 Simpson technique . Intervention 2: In the control group if there is pain, will prescribe Morphine Sulfate 3 mg IV every 6 hours. Pain score using Visual Analogue Scale for 0.5, 1, 2, 4, 6, 12, 18 and 24 hours after MI is measured. Also in 0.5 , 1, 2, 4, 6, 12, 18 and 24 hours post-MI patients' blood pressure and heart rate will be measured . All patients underwent echocardiography 3 days and 6 weeks after MI then ischemic complications involving Hypokinesia, Akinesia and Dyskinesia and Ejection Fraction will be measure by Simpson technique .</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Behzad Roozbahani MD</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ekbatan Hospital- Hamadan-Iran</address>
        <city>Hamedan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 81 3825 1244</telephone>
        <email>behzadroozbahani@gmail.com</email>
        <affiliation>Hamedan university of medical science</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Bakhshaei shahrbabaki Mohammad Hossein MD</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Operating room Teather- Ekbatan Hospital- Hamadan</address>
        <city>Hamedan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 81382512445</telephone>
        <email>bakhshaei@umsha.ac.ir</email>
        <affiliation>Hamehan University of  Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: 40-80 years old patients ؛ who admitted to  Hamedan Ekbatan hospital with using signs and ECG for the detection of myocardial infarction .&#13;
  Exclusion criteria: systolic blood pressure less than 100 mm Hg or greater than 200 mm Hg ؛ diastolic blood pressure below 60 mm Hg ؛ history of previous myocardial infarction ؛ fibrinolytic therapy or revascularization ؛ hepatic and renal disease ؛ addiction to Opium consumption ؛ VAS(Visual Analogue Scale)  greater than 3 ؛ loss of consciousness.</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I 21 , I 2</hc_code>
      <hc_code>R00 , R01 </hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acute myocardial infarction  Incl.:myocardial infarction specified as acute or with a stated duration of 4 weeks (28 days) or less from onsetExcl.:certain current complications following acute myocardial infarction (I23.-) myocardial infarction:•old (I25.</hc_keyword>
      <hc_keyword>Cardiac murmurs and other cardiac sounds  ؛ Abnormalities of heart beat ؛  Pain in throat and chest ؛ Other symptoms and signs involving the circulatory and respiratory systems ؛</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>All patients will receive  initial treatment of myocardial infarction in arrival emergency department.The treatment consists of oxygen by nasal, oral aspirin 325 mg, sublingual nitrate for up to 3 doses and initial dose of intravenous morphine 3 mg .&#13;
The intervention group will receive 4 doses of acetaminophen 1 gram intravenously every 6 hours, dissolved in 100 mL of normal saline. &#13;
 Methods: 70 pack of dark colors written on them from 1 to 70 are randomly divided into two groups of 35.Inside each envelope is a card on which the letters A (acetaminophen treatment group) or the letter B (morphine treatment group) is written.The letter A or B can be placed inside the envelope are determined using a random numbers table.The first patient to be admitted, we're open Envelope 1 , and patients indicates that the card is inserted into envelopes .Similarly, during the study,for each patient who is eligible for inclusion special envelopes will be opened by the numbers and them placed in the specified group.Pain score using Visual Analogue Scale for0, 0.5, 1, 2, 4, 6, 12, 18 and 24 hours after MI is measured.   Also in 0 , 0.5 , 1, 2, 4, 6, 12, 18 and 24 hours post-MI patients' blood pressure and heart rate will be measured .&#13;
 All patients underwent echocardiography 3 days and 6 weeks after MI then ischemic complications involving Hypokinesia, Akinesia and Dyskinesia  and Ejection Fraction will be measure by&#13;
 Simpson technique .</i_keyword>
      <i_keyword>In the control group if there is pain, will prescribe Morphine Sulfate 3 mg IV every 6 hours. Pain score using Visual Analogue Scale for 0.5, 1, 2, 4, 6, 12, 18 and 24 hours after MI is measured. Also in 0.5 , 1, 2, 4, 6, 12, 18 and 24 hours post-MI patients' blood pressure and heart rate will be measured . All patients underwent echocardiography 3 days and 6 weeks after MI then ischemic complications involving Hypokinesia, Akinesia and Dyskinesia and Ejection Fraction will be measure by Simpson technique .</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Myocardial infarction pain. Timepoint: 0,0.5,1,2,4,6,12,18,24 hours after myocardial infarction. Method of measurement: Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Heart rate. Timepoint: 0,0.5,1,2,4,6,12,18,24 hours after myocardial infarction. Method of measurement: Holter monitoring.</prim_outcome>
      <prim_outcome>Arterial blood pressure. Timepoint: 0,0.5,1,2,4,6,12,18,24 hours after myocardial infarction. Method of measurement: Holter monitoring.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Cardiac function. Timepoint: 3rd and 42th days after myocardial infarction. Method of measurement: by Echocardiograghy.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for research Hamehan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2014-06-25</approval_date>
        <contact_name>Ethics Committee of Hamehan University of  Medical Sciences</contact_name>
        <contact_address>University of  Medical Sciences,Shahid Fahmideh boulevard Hamedan  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
